OC-Plex Tumor-on-Chip Platform

From Scientific Evidence
to Confident Drug Decisions

Request a Scientific Consultation
Explore the Platform
OC-Plex tumor-on-chip platform key metrics: over 95% of oncology candidates fail in clinical development, 90%+ clinical concordance in prospective IIT trial, Z-prime greater than 0.5 assay qualification, 4 to 21 day model duration with over 85% tumor viability

The Challenge

Traditional Models Fail to Predict Human Response

Every development stage requires confident evidence for critical Go/No-Go decisions. The models most teams rely on can’t provide it.

The OC-Plex Platform

A Human Tumor Microenvironment — Reconstituted in vitro

Image 1
Image 2
Image 3
Image 4
Image 5
Image 6
Discuss Your Program With Us

Why Xellar

The Only Platform With Every Capability Your Program Needs

“We already have organoids — why do we need this?” Here is the practical cost of settling for less.

Scientific Credibility

Platform Qualification: Decision-Quality Data, Peer-Reviewed

OC-Plex has been validated across reproducibility, biological identity, and TME reconstitution — published in top-tier journals.

Working With Xellar

From First Conversation to Go/No-Go Recommendation

Studies complete in ~2 weeks from sample receipt. We deliver an interpreted report — not a data dump.

Why Leading Teams Choose Xellar

Six Capabilities That Set Xellar Apart

Studies complete in ~2 weeks from sample receipt. We deliver an interpreted report — not a data dump.

Get Started

Ready to Make Confident
Drug Development Decisions?

Start with a 30-minute scientific consultation. We’ll match your program to the right application — no commitment required.
Schedule a Consultation
Contact Our Science Team
Back
outreach@xellarbio.com
Viber
WhatsApp
Twitter
Linkedin

Contact Us

Leave us a request and we will contact you soon.